64 filings
8-K
ME
23andMe Holding Co - Ordinary Shares
10 May 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
ME
23andMe Holding Co - Ordinary Shares
18 Apr 24
23andMe announces CEO’s intention to pursue a potential take-private
8:07am
8-K
ME
23andMe Holding Co - Ordinary Shares
29 Mar 24
Departure of Directors or Certain Officers
12:46pm
8-K
ME
23andMe Holding Co - Ordinary Shares
7 Feb 24
23andMe Reports Third Quarter Fiscal 2024 Financial Results
4:03pm
8-K
ME
23andMe Holding Co - Ordinary Shares
31 Jan 24
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
7:50am
8-K
7oxc6
8 Jan 24
Regulation FD Disclosure
7:45am
8-K/A
pcj65hg2w7cm
1 Dec 23
Regulation FD Disclosure
4:06pm
8-K
uar stpvq1
13 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
mz1m68efhiec1qs1
8 Nov 23
23andMe Reports Second Quarter Fiscal 2024 Financial Results
4:29pm
8-K
4h6mpktyg6
6 Nov 23
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
8:15am
8-K
bbmrl26c
30 Oct 23
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
4:05pm
8-K
xsf 0rtql7f
27 Oct 23
Departure of Directors or Certain Officers
4:06pm
8-K
16f 56ln51hokz39
10 Oct 23
Regulation FD Disclosure
4:17pm
8-K
g4yul2w
19 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
f1ldfko0 hs3xfwe4zp
11 Sep 23
Departure of Directors or Certain Officers
4:06pm
8-K
e059npipn9nh hxjy7j
1 Sep 23
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
12:00am
8-K
qbn 5o7cku
8 Aug 23
23andMe Reports FY2024 First Quarter Financial Results
4:10pm
8-K
dcjkac9303qew
9 Jun 23
Cost Associated with Exit or Disposal Activities
4:05pm
8-K
l7h o81zhzmycql9w7t6
25 May 23
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
4:08pm
8-K
1gjfbyj a0c0lu9w
17 Apr 23
Regulation FD Disclosure
4:10pm